Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.37−0.06 (-4.20%)
Close on Nov 18, 2026Market cap $32.61MP/E –Yield –
Kalaris Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kalaris Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$47.76M. For fiscal 2025 it was -$46.15M. The highest annual figure on record is -$26.70M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$46.15M | – |
| FY2024 | Dec 31, 2024 | -$51.73M | – |
| FY2023 | Dec 31, 2023 | -$199.90M | – |
| FY2022 | Dec 31, 2022 | -$171.20M | – |
| FY2021 | Dec 31, 2021 | -$169.82M | – |
| FY2020 | Dec 31, 2020 | -$71.31M | – |
| FY2019 | Dec 31, 2019 | -$26.70M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$62.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$43.19M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.80M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.90M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.15M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.84M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.95M | – |
See a number that looks wrong?